Cytokinetics' cardiac myosin inhibitor Myqorzo has succeeded where first-to-market Camzyos from Bristol Myers Squibb failed, hitting the mark in a phase 3 trial in non-obstructive hypertrophic ...
The full data from AstraZeneca's phase 3 BaxHTN trial of baxdrostat has raised hope of an important new treatment option for people who struggle to control their blood pressure with current therapies.
Specifically, the MHRA approved Zynyz as a first- and second-line treatment for adults with advanced squamous cell carcinoma ...
Earlier this year I was sent a certificate showing 99.6% purity. It had a lab name, a test date, and a clean chromatogram. It ...
The approval gives Lilly first-mover advantage in China – the world's second-largest pharma market – and an edge over Novo, ...
Hims & Hers is also offering compounded formulations of other unapproved peptides, including sermorelin, which some people ...
The FDA has ordered all GLP-1 receptor agonist manufacturers to add a warning to the label of their products for a rare eye ...
Asundexian has been approved by the FDA under the Sunharbo brand name for use in combination with antiplatelet therapy to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results